Richard H Simon
Overview
Explore the profile of Richard H Simon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carmody L, Caverly L, Kalikin L, Thornton C, Simon R, VanDevanter D, et al.
J Cyst Fibros
. 2024 Dec;
PMID: 39627109
Treatment-associated differences in Pseudomonas aeruginosa (Pa) density in sputum have been used as a response biomarker in clinical trials of cystic fibrosis (CF) therapies. Although most studies have included placebo-treated...
2.
Quittell L, Simon R, Morgan W
J Cyst Fibros
. 2024 May;
23(4):734-738.
PMID: 38719765
This manuscript addresses the development and operating procedures of the Cystic Fibrosis Foundation Data Safety Monitoring Board (CFF-DSMB) and its role in the development and approval of new therapies through...
3.
Jia S, Wang Y, Ross M, Zuckerman J, Murray S, Han M, et al.
J Cyst Fibros
. 2024 Mar;
23(5):878-884.
PMID: 38490920
Background: Iron deficiency (ID) is a common extrapulmonary manifestation in cystic fibrosis (CF). CF transmembrane conductance regulator (CFTR) modulator therapies, particularly highly-effective modulator therapy (HEMT), have drastically improved health status...
4.
Simon R, Quittell L, Morgan W
J Cyst Fibros
. 2023 Dec;
23(1):65-67.
PMID: 38151411
No abstract available.
5.
Quittell L, Morgan W, Simon R
J Cyst Fibros
. 2023 Sep;
22(4):596-597.
PMID: 37679269
No abstract available.
6.
Thornton C, Magaret A, Carmody L, Kalikin L, Simon R, LiPuma J, et al.
J Cyst Fibros
. 2023 May;
23(2):321-328.
PMID: 37244842
Background: Home spirometry is increasingly used to monitor lung function in people with cystic fibrosis (pwCF). Although decreases in lung function in the setting of increased respiratory symptoms are consistent...
7.
Lipp M, Crass R, Fitzgerald L, Patel T, Simon R, Lenhan B, et al.
J Antimicrob Chemother
. 2022 Jun;
77(9):2516-2521.
PMID: 35678460
Objectives: Colistimethate sodium and tobramycin are important systemic antibiotics for treatment of cystic fibrosis (CF) pulmonary exacerbations but can induce acute kidney injury (AKI). We characterize the rate of AKI...
8.
Carmody L, Kalikin L, VanDevanter D, Li G, Opron K, Simon R, et al.
J Cyst Fibros
. 2022 Jun;
21(5):766-768.
PMID: 35667975
Chronic polymicrobial airway infections are a hallmark of cystic fibrosis (CF) lung disease. Antibiotic therapy is a primary treatment of CF pulmonary exacerbations (PEx); however, the impact of episodic antibiotic...
9.
Lusman S, Borowitz D, Marshall B, Narkewicz M, Gonska T, Grand R, et al.
J Cyst Fibros
. 2020 Aug;
20(4):586-590.
PMID: 32736950
Individuals with cystic fibrosis (CF) now have an increased life expectancy, due to advances in care provided by a multidisciplinary team. The care model has expanded over time to include...
10.
Lu J, Carmody L, Opron K, Simon R, Kalikin L, Caverly L, et al.
mSystems
. 2020 Jul;
5(4).
PMID: 32636336
Culture-independent studies of the cystic fibrosis (CF) airway microbiome typically rely on expectorated sputum to assess the microbial makeup of lower airways. These studies have revealed rich bacterial communities. There...